Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Fludarabine
Drug: Novantrone
Drug: Decadron
Drug: Interferon
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Bleomycin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Cisplatin
Drug: Ara-C
Drug: Methyl-Prednisolone
Drug: Procarbazine
Drug: Prednisone

First Posted Date: 2007-12-20

Last Posted Date: 2020-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 210

Registration Number: NCT00577993

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: etoposide
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: intensity-modulated radiation therapy
Radiation: tomotherapy

First Posted Date: 2007-12-19

Last Posted Date: 2024-04-02

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 51

Registration Number: NCT00576979

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cisplatin
Drug: carboplatin
Drug: pemetrexed disodium
Drug: etoposide
Drug: sorafenib tosylate

First Posted Date: 2007-12-14

Last Posted Date: 2012-04-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 31

Registration Number: NCT00573690

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Velcade
Drug: Thalidomide
Drug: Dexamethasone
Drug: Adriamycin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2007-12-12

Last Posted Date: 2024-04-10

Lead Sponsor: University of Arkansas

Target Recruit Count: 177

Registration Number: NCT00572169

Locations: 🇺🇸
University of Arkansas for Medical Sciences/Myeloma Institute, Little Rock, Arkansas, United States

Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells
Drug: carmustine
Drug: cyclophosphamide
Drug: etoposide
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-12-10

Last Posted Date: 2019-11-15

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 5

Registration Number: NCT00569985

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Phase 3

Completed

Conditions: Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Recurrent Neuroblastoma
Regional Neuroblastoma
Stage 4 Neuroblastoma
Stage 4S Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Biological: Filgrastim
Drug: Isotretinoin
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Drug: Topotecan Hydrochloride
Drug: Thiotepa
Drug: Vincristine Sulfate Liposome

First Posted Date: 2007-12-05

Last Posted Date: 2022-04-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 665

Registration Number: NCT00567567

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States

and more 187 locations

Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: etoposide
Procedure: AHSCT
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2007-11-26

Last Posted Date: 2021-06-18

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 54

Registration Number: NCT00562978

Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: cyclophosphamide
Drug: carmustine
Drug: etoposide
Procedure: autologous hematopoietic stem cell transplantation
Radiation: total-body irradiation
Procedure: peripheral blood stem cell transplantation
Drug: G-CSF

First Posted Date: 2007-11-16

Last Posted Date: 2015-08-11

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 60

Registration Number: NCT00559104

Locations: 🇺🇸
Good Samaritan Regional Medical Center, Phoenix, Arizona, United States
🇺🇸
City of Hope National Medical Center--Main Campus, Duarte, California, United States

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Acute Undifferentiated Leukemia
Acute Lymphoblastic Leukemia
Childhood T Acute Lymphoblastic Leukemia

Interventions: Drug: Asparaginase
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Procedure: Echocardiography
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Lestaurtinib
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Methylprednisolone
Procedure: Multigated Acquisition Scan
Drug: Pegaspargase
Other: Pharmacological Study
Drug: Prednisone
Drug: Therapeutic Hydrocortisone
Drug: Vincristine Sulfate

First Posted Date: 2007-11-12

Last Posted Date: 2024-07-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 218

Registration Number: NCT00557193

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

and more 167 locations

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma
POOR PROGNOSIS

Interventions: Drug: Rituximab
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone
Drug: Granulocyte-colony-stimulating factor
Drug: Mitoxantrone
Drug: Cytarabine ARA-C
Drug: Dexamethasone
Drug: Carmustine BCNU
Drug: Etoposide
Drug: Melphalan
Radiation: Radiotherapy
Procedure: PBSC reinfusion

First Posted Date: 2007-11-09

Last Posted Date: 2007-11-09

Lead Sponsor: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

Target Recruit Count: 94

Registration Number: NCT00556127

Locations: 🇮🇹
Centro Trapianti Midollo Osseo, P.O. Businco, Cagliari, Italy
🇮🇹
Ospedale S. Gerardo, Monza, Italy
🇮🇹
Osp. maggiore della Carità, Novara, Italy

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy